Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

492 results about "Coenzyme Q10" patented technology

Coenzyme Q, also known as ubiquinone, is a coenzyme family that is ubiquitous in animals and most bacteria (hence the name ubiquinone). In humans, the most common form is Coenzyme Q₁₀ or ubiquinone-10. CoQ₁₀ is not approved by the U.S. Food and Drug Administration (FDA) for the treatment of any medical condition. It, however, is sold as a dietary supplement.

Pharmaceutical composition and method for the transdermal delivery of calcium

The present invention relates to a method and transdermal pharmaceutical composition for preventing or reducing the likelihood of calcium deficiency or imbalances caused by calcium deficiency. The transdermal pharmaceutical composition includes a therapeutically effective amount of a pharmaceutically acceptable salt of calcium and a pharmaceutically acceptable carrier constituting a pluronic lecithin organogel. In addition to calcium, the transdermal pharmaceutical composition may also contain a therapeutically effective amount of: (1) a pharmaceutically acceptably salt of other minerals such as magnesium, zinc, selenium, manganese, or chromium; (2) a vitamin such as vitamin A, vitamin D, vitamin C, vitamin E or B-complex vitamins, choline, lecithin, inositol, PABA, biotin, or bioflavomoids; (3) a carotenoid such as lycopene or lutein; (4) a hormone such as dehydroepiandrosterone, progesterone, pregnenolone, or melatonin; (5) an amino acid such as arginine, glutamine, lysine, phenylalanine, tyrosine, GABA, tryptophan, carnitine, or acetyl-l-carnitine; (6) a fatty acid such as a fish oil or flax seed oil; (7) a vita-nutrient such as coenzyme Q10; (8) a cartilage building nutrient such as glucosamine, chondroitin, or MSM, (9) a herb such as ginkgo biloba, echinacea, 5-HTP, St. John's wort, or saw palmetto; or (9) any combination thereof. The transdermal pharmaceutical composition may be topically administered to a human to prevent or reduce the likelihood of calcium deficiency or imbalances caused by calcium deficiency such as hypertension, high cholesterol, colon and rectal cancer, osteomalacia, rickets, osteoporosis, cardiovascular disease, preeclampsia, tooth decay, and premenstrual syndrome.
Owner:BRIERRE BARBARA T

INTRAVENOUS FORMULATIONS OF COENZYME Q10 (CoQ10) AND METHODS OF USE THEREOF

Disclosed herein are formulations suitable for parenteral administration of certain hydrophobic active agents such as Coenzyme Q10. Methods of preparing the same and methods of treatment of oncological disorders using the same are also provided herein. The formulations comprise an aqueous solution; a hydrophobic active agent dispersed to form a colloidal nano-dispersion of particles; and at least one of a dispersion stabilizing agent and an opsonization reducer wherein the colloidal nano-dispersion of the active agent is dispersed into nano-dispersion particles having a mean size of less than 200-nm. Methods of preparing the parenteral formulations comprise dispersing the hydrophobic active agent by high pressure homogenization by (1) adding hydrophobic active agent to a 65° C. bath of water and mixing to form a hydrophobic active agent / water mixture; (2) adding a dispersion stabilizing agent to the hydrophobic active agent / water mixture and mix at 65° C. to form a hydrophobic active agent / water / stabilizer mixture; (3) adding an opsonization reducer to form a hydrophobic active agent / water / stabilizer / reducer mixture; (4) pre-heating a Microfluidizer to 65° C.; and (5) processing by mixing the hydrophobic active agent / water / stabilizer / reducer mixture in the Microfluidizer at 65° C. such that a hydrophobic active agent colloidal nano-dispersion having a mean particle size less than 200-nm is formed. Provided herein are also methods of treating oncological disorders by administering formulations described herein to a subject such that treatment or prevention of the oncological disorder occurs.
Owner:BPGBIO INC

Method of stabilizing reduced coenzyme q10

The present invention provides a stabilization method, a preservation method and the like method of reduced coenzyme Q10, which is useful as functional nutritive foods, specific health foods and the like. Furthermore, the present invention provides a method for efficiently obtaining reduced coenzyme Q10 of high quality and by a method suitable for a commercial production.
It is possible to handle and stably preserve reduced coenzyme Q10 under a condition that oxidation by a molecular oxygen is inhibited by contacting reduced coenzyme Q10 with an ascorbic acid and citric acid or a related compound thereof, and thus a stabilized composition is obtained. Moreover, reduced coenzyme Q10 is converted into a crystalline state in such a condition that the formation of oxidized coenzyme Q10 as a byproduct is minimized by crystallizing reduced coenzyme Q10 in the presence of ascorbic acid or a related compound thereof, etc., and thus a reduced coenzyme Q10 crystal of high quality is produced. Furthermore, by successively crystallizing the generated reduced coenzyme Q10 in the presence of ascorbic acid or a related compound thereof after reducing oxidized coenzyme Q10 to reduced coenzyme Q10 using ascorbic acid or a related compound thereof, operations are simplified and minimized, and thus reduced coenzyme Q10 of high quality is produced.
Owner:KANEKA CORP

Dermatological pharmaceutical composition for the treatment of skin inflammation diseases, such as dermatitis, atopic dermatitis, vitiligo, alopecia areata, acne, psoriasis, pruritus or combinations of same

The invention relates to a dermatological pharmaceutical composition for the treatment of skin inflammation diseases, such as dermatitis, atopic dermatitis, vitiligo, alopecia areata, acne, psoriasis and pruritus. The invention comprises a base anti-inflammatory agent, such as indometacin; one or more optional active ingredients selected alternatively from among at least a corticoid and an antibiotic; and a combination of topical antioxidants used to potentiate the anti-inflammatory effect, selected from among green tea, lipoic acid, curcumin, ascorbyl palmitate, Coenzyme Q10, resveratrol, Pycnogenol™, L-camosine, taurine, vitamin E, vitamin C, papaya extract, isoflavones, manganese, lycopene and quercetin. At least one of the topical antioxidants is a peroxisome proliferator-activated receptor-gamma (PPAR-γ) activator. The invention also includes at least one antioxidant substance with an antiproliferative effect on keratonocytes, e.g. manganese, and at least one substance that blocks tumour necrosis factor-alpha (TNF-α) or other cytokines that provoke the acute phase of the inflammatory reaction, also with an antiproliferative effect, e.g. pentoxifylline.
Owner:UMBERT MILL IGNACIO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products